Sangamo Therapeutics

Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer

Retrieved on: 
星期二, 五月 16, 2023
Biotechnology, Pharmaceutical, Genetics, Health, Fabry, Central nervous system, University, MorphoSys, Internal medicine, Head, China Executive Leadership Academy in Pudong, Drug, Patient, Molecular Partners, Novo Nordisk, Therapy, Pharmaceutical industry, Biopharmaceutical, Hematology, Sangamo Therapeutics

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer.
  • “We are thrilled to welcome Dr. Rojkjaer, an experienced physician, drug developer, and regulatory expert, to the Sangamo team,” said Nathalie Dubois-Stringfellow, Chief Development Officer at Sangamo.
  • She has held several senior leadership positions in both clinical development and medical affairs in biotech and global pharmaceutical companies, having most recently served as Chief Medical Officer at Viracta Therapeutics.
  • Other previous roles include Chief Medical Officer at Molecular Partners, and VP, Head of Clinical Development at MorphoSys AG.

Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Retrieved on: 
星期二, 五月 2, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Creutzfeldt–Jakob disease, Central nervous system, Gene, Prevalence, DSM-IV codes, Research, Flexible, AAV, Pain, Nav1.7, Patient, Neuropathic pain, Engineering, Cell, Therapy, Society, Vaccine, Powder metallurgy, Sangamo Therapeutics

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 14 Sangamo abstracts for presentation at the 26th ASGCT Annual Meeting being held May 16-20, 2023, in-person in Los Angeles, CA and in a virtual format.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 14 Sangamo abstracts for presentation at the 26th ASGCT Annual Meeting being held May 16-20, 2023, in-person in Los Angeles, CA and in a virtual format.
  • Presentations will focus on the progression of Sangamo’s pre-clinical programs, including data from the prioritized neurology programs Nav1.7 and Prion, innovations in the epigenetic regulation platform and advances in AAV capsid engineering for delivery.
  • Additional presentations at the ASGCT Annual Meeting will showcase how Sangamo is advancing its proprietary zinc finger platform development efforts, including the use of zinc finger transcriptional regulators designed to reduce the expression of the Prion protein for the treatment of Creutzfeldt-Jakob disease.
  • Sangamo will also present data from its proprietary AAV capsid discovery platform SIFTER™, which enables the engineering of AAV capsids with the potential for highly improved central nervous system transduction efficiency, along with broader presentations showcasing Sangamo’s latest genomic engineering platform evolution.

Gene Switch Global Market Report 2023: Numerous Positive Breakthroughs Draw the Attention of Key Pharmaceutical Players - ResearchAndMarkets.com

Retrieved on: 
星期四, 四月 27, 2023
Biotechnology, Genetics, Health, ACT, Graft-versus-host disease, DNA, Partnership, GVHD, Apostles in the New Testament, CRS, Oxygen, CPC, Overalls, Clinical trial, Enzyme, Cell proliferation, Light, DSM-IV codes, Toxicity, Research, Infection, Attention, Gene expression, RNA, Element, TCR, II, Organization, Sangamo Therapeutics, US, TILS, Protein, Cytokine release syndrome, Investment, Patent, Plasmid, OFF, III, Gene, Neurotoxicity, Oligonucleotide, Safety, Geography, Agriculture, Pharmaceutical industry, Vaccine, Video game, Fine chemical, Retail

The report features an extensive study of the current market landscape and future opportunity for the players involved in the development of gene switch.

Key Points: 
  • The report features an extensive study of the current market landscape and future opportunity for the players involved in the development of gene switch.
  • The global gene switch market is anticipated to grow at an annualized growth rate (CAGR) of 14% during the period 2023-2035.
  • Further, North America is anticipated to capture the major share of the gene switch market in 2035.
    Who are the Key Players in the Gene Switch Market?
  • Answer: The global gene switch market is expected to grow at a CAGR of 14%, during the period 2023-2035.

Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results

Retrieved on: 
星期三, 四月 26, 2023
Biotechnology, Pharmaceutical, Genetics, Health, Change, Pfizer, Gene, Head, Biogen, Haemophilia, GAAP, Research, AAV, American Society of Gene and Cell Therapy, Trial of the century, Gene editing, Nav1.7, Novartis, Patient, Investment, Annual general meeting, Cell, Kidney transplantation, MAA, Bank, American Society for Cell Biology, FDA, Therapy, STAAR, Kite, Environment, IND, Fabry disease, Haemophilia A, Society, BLA, Conference, Pharmaceutical industry, Renewable energy, Vaccine, Fine chemical, Video game, Cryptocurrency, Beauty salon, Fabry, Sangamo Therapeutics

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced recent business highlights, including a strategic pipeline prioritization and restructuring, and reported certain preliminary first quarter 2023 financial results.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced recent business highlights, including a strategic pipeline prioritization and restructuring, and reported certain preliminary first quarter 2023 financial results.
  • In addition, R. Andrew Ramelmeier, Ph.D., Executive Vice President, Technical Operations will be leaving the company on July 10, 2023.
  • Sangamo expects to incur approximately $5 million - $7 million in one-time restructuring costs in the second and third quarters of 2023.
  • Sangamo’s full first quarter 2023 financial results will be reflected in a Quarterly Report on Form 10-Q which is expected to be filed no later than May 10, 2023.

Trend Innovations Holding, Inc. Appoints Kenneth L. Waggoner as Chief Executive Officer

Retrieved on: 
星期二, 四月 25, 2023
Loyola University School of Law, Pancreatic cancer, Amgen, US Foods, General counsel, Diabetes, Private law, Public Interest Declassification Board, Telecommunications, Biotechnology, Bachelor of Arts, California State University, OTCQB, Intelligence, Information technology, Research, Line, Orphan drug, Investigational New Drug, Acquisition, Brobeck, Phleger & Harrison, Fortune 500, Artificial intelligence, Biogen, Food, Law, Ascites, Management, Texaco, Chiron, Sangamo Therapeutics

Trend has named Mr. Waggoner to head the Company’s day-to-day operations and provide its strategic direction and corporate focus.

Key Points: 
  • Trend has named Mr. Waggoner to head the Company’s day-to-day operations and provide its strategic direction and corporate focus.
  • Mr. Waggoner has 45 years of experience in management, business operations, and law.
  • Now, he will apply his business expertise to strengthen Trend’s management team and its focus on product development and product pipeline.
  • Simultaneous with the Nasdaq listing, Mr. Waggoner raised approximately $90 million to support PharmaCyte’s worldwide operations and research and development efforts.

Sangamo Therapeutics Announces First Quarter 2023 Conference Call and Webcast

Retrieved on: 
星期三, 四月 19, 2023
Health, Genetics, Other Science, General Health, Science, Pharmaceutical, Biotechnology, Sangamo Therapeutics, Therapy, Pharmaceutical industry

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to release its first quarter 2023 financial results after the market closes on Wednesday, April 26, 2023.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to release its first quarter 2023 financial results after the market closes on Wednesday, April 26, 2023.
  • The Company will hold a conference call at 8:30 a.m.
  • During the conference call, the company will review its financial results and provide business updates.
  • The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations .

Beam Therapeutics Appoints Gopi Shanker, Ph.D., as Chief Scientific Officer

Retrieved on: 
星期二, 三月 21, 2023
Amgen, DNA, Novartis Institute for Tropical Diseases, Drug development, Icahn School of Medicine at Mount Sinai, Regeneron Pharmaceuticals, CSO, Indian Institute of Science Education and Research, Thiruvananthapuram, Biotechnology, Howard Hughes Medical Institute, Research, Mount Sinai, Biomedical Research, Neuroscience, DSM-IV codes, Acquisition, Novartis, Patient, Hematology, Drug discovery, Cadent, Therapy, Stanley Center for Psychiatric Research at Broad Institute, Genome, Pharmaceutical industry, Beam, Sangamo Therapeutics

CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Gopi Shanker, Ph.D., has been appointed as chief scientific officer (CSO).

Key Points: 
  • CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Gopi Shanker, Ph.D., has been appointed as chief scientific officer (CSO).
  • Dr. Shanker is a scientific leader with more than 20 years of drug development experience as well as experience with novel genetic medicine modalities.
  • Dr. Shanker will report to Giuseppe Ciaramella, Ph.D., president of Beam, who has broad oversight of Beam’s research, manufacturing, regulatory, quality and pharmaceutical sciences organizations.
  • “We are thrilled to welcome Gopi to the Beam team during this exciting time as we advance our diverse clinical and earlier-stage pipeline of base editing programs,” said Dr. Ciaramella.

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
星期三, 二月 22, 2023
Biotechnology, Pharmaceutical, Genetics, Health, Pfizer, Grade 2, Therapy, Central nervous system, Sickle cell disease, STAAR, IND, BLA, ERT, FDA, Patient, Fabry disease, Haemophilia, ASH, CNS, Plasma, Fetal hemoglobin, CMC, Acceleration, AAV, Kite, Society, Biogen, Novartis, Enzyme replacement therapy, Pharmaceutical industry, Vaccine, Video game, Sangamo Therapeutics, Fabry, Chemistry, Sanofi

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2022 financial results.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2022 financial results.
  • All five patients who began the dose escalation phase on enzyme replacement therapy (ERT) had been successfully withdrawn from ERT and remain off ERT today.
  • Revenues for the fourth quarter ended December 31, 2022 were $27.2 million, compared to $28.0 million for the same period in 2021.
  • These increases were partially offset by decreases of $13.9 million in revenue related to our collaboration agreement with Biogen.

Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease

Retrieved on: 
星期三, 二月 22, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Female, Therapy, Central nervous system, Annual report, Southwest General Health Center, Week, Sangamo Therapeutics, Form, Heart, STAAR, Cell, ERT, Marie Cassidy, Patient, Fabry disease, Trial of the century, Plasma, Kidney, Pathology, PTC, Urine, Good Samaritan Hospital Medical Center (West Islip, New York), Data, Pharmaceutical industry, MD, Eastern Time Zone, Fabry

These data, which present new biomarker data and results from the first kidney biopsies in this study, indicate evidence of clinical benefit for isaralgagene civaparvovec in Fabry disease.

Key Points: 
  • These data, which present new biomarker data and results from the first kidney biopsies in this study, indicate evidence of clinical benefit for isaralgagene civaparvovec in Fabry disease.
  • “Fabry is a debilitating disease with life-long impact,” said Dr. Robert Hopkin, MD, Cincinnati Children’s Hospital Medical Center, and investigator of the Phase 1/2 study.
  • Dosing of the remaining patients in the expansion phase of the Phase 1/2 STAAR study is ongoing, with a total of 20 sites active and recruiting.
  • Dosing of the first patient in the Phase 3 trial could begin as early as the first part of 2024.

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast

Retrieved on: 
星期二, 二月 21, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Sangamo Therapeutics, Therapy, Pharmaceutical industry

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to hold a conference call on Wednesday, February 22, 2023 at 4:30 p.m.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to hold a conference call on Wednesday, February 22, 2023 at 4:30 p.m.
  • ET to review its fourth quarter and full year 2022 financial results and business updates.
  • Prior to the call, the company will have released its fourth quarter and full year financial results.
  • The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events .